Topera Maps Abnormal Currents of the Heart, Novalar Plans Shutdown, New Verenium CEO Drafts Strategy, & More San Diego Life Sciences News
San Diego’s life sciences community took two steps forward last week, as two new startups stepped into the light with new medical device technologies, and then one step back with the closure of another company founded in 2000. We have all the latest moves for you, plus a lot more.
—San Diego’s Topera Medical, which has maintained a low profile since it was launched three years ago, established a Lexington, MA-headquarters to commercialize technology developed by UC San Diego cardiologist Sanjiv Narayan. Topera, which hired former Boston Scientific executive Edward Kerslake as CEO, has technology designed to map the heart’s abnormal electrical currents, which occur with irregular heartbeats like atrial fibrillation.
—San Diego-based OncoSec, which was created March 1 through a reverse merger with a dormant public company, says it has licensed drug delivery technology from Innovio Pharmaceuticals to improve the efficacy of certain anti-cancer drugs. Inovio’s electroporation technology uses brief pulses of electricity to temporarily increase the permeability of cell walls, making it easier for OncoSec’s conventional chemotherapy drugs to penetrate cancerous tumors.
—San Diego’s Novalar Pharmaceuticals sold its only product, an FDA-approved drug for reversing the numbing effects of dental anesthesia, and will shut down in coming weeks. The French dental medication company Septodont acquired … Next Page »